Ultragenyx Pharmaceutical (RARE) Receivables - Net (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Receivables - Net data on file, last reported at $121.0 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $121.0 million, up 196.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $121.0 million (up 196.57% YoY), and the FY2025 annual result was $158.0 million, up 85.88% from the prior year.
• Receivables - Net slipped to $121.0 million in Q1 2026 per RARE's latest filing, from $158.0 million in the prior quarter.
• Over five years, Receivables - Net peaked at $158.0 million in Q4 2025 and troughed at $1.7 million in Q3 2025.
• A 5-year average of $58.5 million and a median of $43.0 million in 2023 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2023 and 2025: Receivables - Net jumped 421.47% in 2023, then plunged 96.96% in 2025.
• A 5-year view of Receivables - Net shows it stood at $27.5 million in 2022, then surged by 42.55% to $39.2 million in 2023, then surged by 116.84% to $85.0 million in 2024, then surged by 85.88% to $158.0 million in 2025, then fell by 23.42% to $121.0 million in 2026.
• Business Quant data shows RARE's Receivables - Net at $121.0 million in Q1 2026, $158.0 million in Q4 2025, and $1.7 million in Q3 2025.